nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—Topoisomerase Inhibitors—Irinotecan—colon cancer	0.479	1	CiPCiCtD
Mitoxantrone—breast cancer—colon cancer	0.258	1	CtDrD
Mitoxantrone—ABCB1—colon cancer	0.0771	1	CbGaD
Mitoxantrone—ABCC1—Irinotecan—colon cancer	0.0213	0.182	CbGbCtD
Mitoxantrone—ABCC1—Vincristine—colon cancer	0.0186	0.159	CbGbCtD
Mitoxantrone—ABCG2—Irinotecan—colon cancer	0.0142	0.122	CbGbCtD
Mitoxantrone—ABCG2—Fluorouracil—colon cancer	0.0137	0.117	CbGbCtD
Mitoxantrone—ABCG2—Vincristine—colon cancer	0.0124	0.106	CbGbCtD
Mitoxantrone—ABCC1—Methotrexate—colon cancer	0.0113	0.0961	CbGbCtD
Mitoxantrone—ABCG2—Methotrexate—colon cancer	0.00753	0.0643	CbGbCtD
Mitoxantrone—ABCB1—Irinotecan—colon cancer	0.00513	0.0438	CbGbCtD
Mitoxantrone—ABCB1—Vincristine—colon cancer	0.00449	0.0383	CbGbCtD
Mitoxantrone—CYP3A4—Irinotecan—colon cancer	0.00307	0.0263	CbGbCtD
Mitoxantrone—ABCB1—Methotrexate—colon cancer	0.00272	0.0232	CbGbCtD
Mitoxantrone—CYP3A4—Vincristine—colon cancer	0.00269	0.023	CbGbCtD
Mitoxantrone—SLC47A2—renal system—colon cancer	0.00086	0.0693	CbGeAlD
Mitoxantrone—SLC47A2—digestive system—colon cancer	0.000705	0.0568	CbGeAlD
Mitoxantrone—SLC47A2—vagina—colon cancer	0.000623	0.0502	CbGeAlD
Mitoxantrone—PIM1—renal system—colon cancer	0.000562	0.0452	CbGeAlD
Mitoxantrone—BTK—lymphoid tissue—colon cancer	0.000538	0.0434	CbGeAlD
Mitoxantrone—BTK—bone marrow—colon cancer	0.00049	0.0395	CbGeAlD
Mitoxantrone—BTK—vagina—colon cancer	0.00047	0.0378	CbGeAlD
Mitoxantrone—PIM1—lymphoid tissue—colon cancer	0.000466	0.0376	CbGeAlD
Mitoxantrone—PIM1—digestive system—colon cancer	0.000461	0.0371	CbGeAlD
Mitoxantrone—PIM1—bone marrow—colon cancer	0.000425	0.0342	CbGeAlD
Mitoxantrone—PIM1—vagina—colon cancer	0.000407	0.0328	CbGeAlD
Mitoxantrone—BTK—liver—colon cancer	0.000396	0.0319	CbGeAlD
Mitoxantrone—TOP2A—Topotecan—Irinotecan—colon cancer	0.000387	0.404	CbGdCrCtD
Mitoxantrone—PIM1—liver—colon cancer	0.000343	0.0276	CbGeAlD
Mitoxantrone—BTK—lymph node—colon cancer	0.000304	0.0245	CbGeAlD
Mitoxantrone—SLC47A1—renal system—colon cancer	0.000301	0.0242	CbGeAlD
Mitoxantrone—TOP2A—Vindesine—Vincristine—colon cancer	0.000277	0.289	CbGdCrCtD
Mitoxantrone—PIM1—lymph node—colon cancer	0.000263	0.0212	CbGeAlD
Mitoxantrone—TOP2A—bone marrow—colon cancer	0.000249	0.0201	CbGeAlD
Mitoxantrone—SLC47A1—digestive system—colon cancer	0.000247	0.0199	CbGeAlD
Mitoxantrone—TOP2A—vagina—colon cancer	0.000239	0.0192	CbGeAlD
Mitoxantrone—CYP1B1—smooth muscle tissue—colon cancer	0.000229	0.0185	CbGeAlD
Mitoxantrone—CYP1B1—renal system—colon cancer	0.000221	0.0178	CbGeAlD
Mitoxantrone—SLC47A1—vagina—colon cancer	0.000218	0.0176	CbGeAlD
Mitoxantrone—SLC47A1—liver—colon cancer	0.000184	0.0148	CbGeAlD
Mitoxantrone—CYP1B1—lymphoid tissue—colon cancer	0.000183	0.0148	CbGeAlD
Mitoxantrone—CYP1B1—digestive system—colon cancer	0.000181	0.0146	CbGeAlD
Mitoxantrone—ABCB1—blood vessel—colon cancer	0.000179	0.0145	CbGeAlD
Mitoxantrone—TOP2A—Vinorelbine—Vincristine—colon cancer	0.000175	0.182	CbGdCrCtD
Mitoxantrone—TOP2A—lymph node—colon cancer	0.000154	0.0124	CbGeAlD
Mitoxantrone—ABCC1—vagina—colon cancer	0.000144	0.0116	CbGeAlD
Mitoxantrone—CYP2E1—renal system—colon cancer	0.000142	0.0115	CbGeAlD
Mitoxantrone—SLC47A1—lymph node—colon cancer	0.000141	0.0114	CbGeAlD
Mitoxantrone—CYP1B1—liver—colon cancer	0.000135	0.0109	CbGeAlD
Mitoxantrone—ABCG2—bone marrow—colon cancer	0.000124	0.01	CbGeAlD
Mitoxantrone—ABCC1—liver—colon cancer	0.000121	0.00977	CbGeAlD
Mitoxantrone—TOP2A—Vinblastine—Vincristine—colon cancer	0.00012	0.125	CbGdCrCtD
Mitoxantrone—ABCG2—vagina—colon cancer	0.000119	0.00958	CbGeAlD
Mitoxantrone—CYP2E1—lymphoid tissue—colon cancer	0.000118	0.00951	CbGeAlD
Mitoxantrone—CYP2E1—digestive system—colon cancer	0.000117	0.0094	CbGeAlD
Mitoxantrone—CYP3A4—renal system—colon cancer	0.000114	0.00922	CbGeAlD
Mitoxantrone—ABCB1—embryo—colon cancer	0.000107	0.00862	CbGeAlD
Mitoxantrone—CYP1B1—lymph node—colon cancer	0.000103	0.00832	CbGeAlD
Mitoxantrone—ABCG2—liver—colon cancer	0.0001	0.00808	CbGeAlD
Mitoxantrone—CYP3A4—digestive system—colon cancer	9.38e-05	0.00756	CbGeAlD
Mitoxantrone—ABCC1—lymph node—colon cancer	9.29e-05	0.00749	CbGeAlD
Mitoxantrone—ABCB1—epithelium—colon cancer	8.73e-05	0.00703	CbGeAlD
Mitoxantrone—CYP2E1—liver—colon cancer	8.69e-05	0.007	CbGeAlD
Mitoxantrone—Pharyngitis—Fluorouracil—colon cancer	8.51e-05	0.00222	CcSEcCtD
Mitoxantrone—Alopecia—Vincristine—colon cancer	8.12e-05	0.00212	CcSEcCtD
Mitoxantrone—Blood creatinine increased—Capecitabine—colon cancer	8.11e-05	0.00212	CcSEcCtD
Mitoxantrone—ABCB1—renal system—colon cancer	8.1e-05	0.00652	CbGeAlD
Mitoxantrone—Dehydration—Capecitabine—colon cancer	8.05e-05	0.0021	CcSEcCtD
Mitoxantrone—Chills—Irinotecan—colon cancer	8.03e-05	0.0021	CcSEcCtD
Mitoxantrone—Ecchymosis—Methotrexate—colon cancer	8.03e-05	0.0021	CcSEcCtD
Mitoxantrone—Arrhythmia—Irinotecan—colon cancer	8e-05	0.00209	CcSEcCtD
Mitoxantrone—Alopecia—Irinotecan—colon cancer	7.91e-05	0.00206	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Capecitabine—colon cancer	7.91e-05	0.00206	CcSEcCtD
Mitoxantrone—Hypokalaemia—Capecitabine—colon cancer	7.88e-05	0.00206	CcSEcCtD
Mitoxantrone—Aspartate aminotransferase increased—Capecitabine—colon cancer	7.8e-05	0.00204	CcSEcCtD
Mitoxantrone—Back pain—Vincristine—colon cancer	7.74e-05	0.00202	CcSEcCtD
Mitoxantrone—Sepsis—Methotrexate—colon cancer	7.71e-05	0.00201	CcSEcCtD
Mitoxantrone—ABCG2—lymph node—colon cancer	7.69e-05	0.0062	CbGeAlD
Mitoxantrone—Arrhythmia—Fluorouracil—colon cancer	7.66e-05	0.002	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Capecitabine—colon cancer	7.64e-05	0.00199	CcSEcCtD
Mitoxantrone—Alopecia—Fluorouracil—colon cancer	7.58e-05	0.00198	CcSEcCtD
Mitoxantrone—Back pain—Irinotecan—colon cancer	7.54e-05	0.00197	CcSEcCtD
Mitoxantrone—Erythema—Fluorouracil—colon cancer	7.46e-05	0.00195	CcSEcCtD
Mitoxantrone—Anaemia—Vincristine—colon cancer	7.4e-05	0.00193	CcSEcCtD
Mitoxantrone—Sweating increased—Capecitabine—colon cancer	7.29e-05	0.0019	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Irinotecan—colon cancer	7.23e-05	0.00189	CcSEcCtD
Mitoxantrone—Anaemia—Irinotecan—colon cancer	7.2e-05	0.00188	CcSEcCtD
Mitoxantrone—Leukopenia—Vincristine—colon cancer	7.16e-05	0.00187	CcSEcCtD
Mitoxantrone—Pancytopenia—Capecitabine—colon cancer	7.11e-05	0.00186	CcSEcCtD
Mitoxantrone—Vision blurred—Fluorouracil—colon cancer	7.03e-05	0.00184	CcSEcCtD
Mitoxantrone—Malaise—Irinotecan—colon cancer	7.03e-05	0.00183	CcSEcCtD
Mitoxantrone—Neutropenia—Capecitabine—colon cancer	7e-05	0.00183	CcSEcCtD
Mitoxantrone—CYP3A4—liver—colon cancer	6.99e-05	0.00563	CbGeAlD
Mitoxantrone—Renal failure acute—Methotrexate—colon cancer	6.98e-05	0.00182	CcSEcCtD
Mitoxantrone—Leukopenia—Irinotecan—colon cancer	6.97e-05	0.00182	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Capecitabine—colon cancer	6.96e-05	0.00182	CcSEcCtD
Mitoxantrone—Convulsion—Vincristine—colon cancer	6.93e-05	0.00181	CcSEcCtD
Mitoxantrone—Hypertension—Vincristine—colon cancer	6.91e-05	0.0018	CcSEcCtD
Mitoxantrone—Anaemia—Fluorouracil—colon cancer	6.9e-05	0.0018	CcSEcCtD
Mitoxantrone—Myalgia—Vincristine—colon cancer	6.81e-05	0.00178	CcSEcCtD
Mitoxantrone—Weight increased—Capecitabine—colon cancer	6.81e-05	0.00178	CcSEcCtD
Mitoxantrone—Cough—Irinotecan—colon cancer	6.8e-05	0.00178	CcSEcCtD
Mitoxantrone—Weight decreased—Capecitabine—colon cancer	6.77e-05	0.00177	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Capecitabine—colon cancer	6.75e-05	0.00176	CcSEcCtD
Mitoxantrone—Hypertension—Irinotecan—colon cancer	6.73e-05	0.00176	CcSEcCtD
Mitoxantrone—ABCB1—lymphoid tissue—colon cancer	6.72e-05	0.00542	CbGeAlD
Mitoxantrone—Pneumonia—Capecitabine—colon cancer	6.71e-05	0.00175	CcSEcCtD
Mitoxantrone—Leukopenia—Fluorouracil—colon cancer	6.68e-05	0.00174	CcSEcCtD
Mitoxantrone—Anaphylactoid reaction—Methotrexate—colon cancer	6.66e-05	0.00174	CcSEcCtD
Mitoxantrone—ABCB1—digestive system—colon cancer	6.64e-05	0.00535	CbGeAlD
Mitoxantrone—Acute coronary syndrome—Capecitabine—colon cancer	6.58e-05	0.00172	CcSEcCtD
Mitoxantrone—Renal failure—Capecitabine—colon cancer	6.56e-05	0.00171	CcSEcCtD
Mitoxantrone—Discomfort—Irinotecan—colon cancer	6.55e-05	0.00171	CcSEcCtD
Mitoxantrone—Myocardial infarction—Capecitabine—colon cancer	6.54e-05	0.00171	CcSEcCtD
Mitoxantrone—Oedema—Vincristine—colon cancer	6.53e-05	0.0017	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Vincristine—colon cancer	6.53e-05	0.0017	CcSEcCtD
Mitoxantrone—Stomatitis—Capecitabine—colon cancer	6.5e-05	0.0017	CcSEcCtD
Mitoxantrone—Jaundice—Capecitabine—colon cancer	6.5e-05	0.0017	CcSEcCtD
Mitoxantrone—Infection—Vincristine—colon cancer	6.49e-05	0.00169	CcSEcCtD
Mitoxantrone—Conjunctivitis—Capecitabine—colon cancer	6.49e-05	0.00169	CcSEcCtD
Mitoxantrone—Urinary tract infection—Capecitabine—colon cancer	6.49e-05	0.00169	CcSEcCtD
Mitoxantrone—Convulsion—Fluorouracil—colon cancer	6.47e-05	0.00169	CcSEcCtD
Mitoxantrone—Confusional state—Irinotecan—colon cancer	6.41e-05	0.00167	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Vincristine—colon cancer	6.39e-05	0.00167	CcSEcCtD
Mitoxantrone—Haematuria—Capecitabine—colon cancer	6.36e-05	0.00166	CcSEcCtD
Mitoxantrone—Oedema—Irinotecan—colon cancer	6.36e-05	0.00166	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Irinotecan—colon cancer	6.36e-05	0.00166	CcSEcCtD
Mitoxantrone—Myalgia—Fluorouracil—colon cancer	6.35e-05	0.00166	CcSEcCtD
Mitoxantrone—Chest pain—Fluorouracil—colon cancer	6.35e-05	0.00166	CcSEcCtD
Mitoxantrone—Infection—Irinotecan—colon cancer	6.32e-05	0.00165	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Vincristine—colon cancer	6.31e-05	0.00165	CcSEcCtD
Mitoxantrone—Discomfort—Fluorouracil—colon cancer	6.28e-05	0.00164	CcSEcCtD
Mitoxantrone—Shock—Irinotecan—colon cancer	6.26e-05	0.00163	CcSEcCtD
Mitoxantrone—Agranulocytosis—Capecitabine—colon cancer	6.23e-05	0.00163	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Irinotecan—colon cancer	6.23e-05	0.00163	CcSEcCtD
Mitoxantrone—Anorexia—Vincristine—colon cancer	6.22e-05	0.00162	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Irinotecan—colon cancer	6.15e-05	0.0016	CcSEcCtD
Mitoxantrone—Confusional state—Fluorouracil—colon cancer	6.14e-05	0.0016	CcSEcCtD
Mitoxantrone—ABCB1—bone marrow—colon cancer	6.12e-05	0.00493	CbGeAlD
Mitoxantrone—Hypotension—Vincristine—colon cancer	6.1e-05	0.00159	CcSEcCtD
Mitoxantrone—Bradycardia—Capecitabine—colon cancer	6.1e-05	0.00159	CcSEcCtD
Mitoxantrone—Oedema—Fluorouracil—colon cancer	6.09e-05	0.00159	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Fluorouracil—colon cancer	6.09e-05	0.00159	CcSEcCtD
Mitoxantrone—Anorexia—Irinotecan—colon cancer	6.06e-05	0.00158	CcSEcCtD
Mitoxantrone—Infection—Fluorouracil—colon cancer	6.05e-05	0.00158	CcSEcCtD
Mitoxantrone—Haemoglobin—Capecitabine—colon cancer	6.02e-05	0.00157	CcSEcCtD
Mitoxantrone—Rhinitis—Capecitabine—colon cancer	6.01e-05	0.00157	CcSEcCtD
Mitoxantrone—Haemorrhage—Capecitabine—colon cancer	5.99e-05	0.00156	CcSEcCtD
Mitoxantrone—Hepatitis—Capecitabine—colon cancer	5.99e-05	0.00156	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Fluorouracil—colon cancer	5.96e-05	0.00156	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Vincristine—colon cancer	5.95e-05	0.00155	CcSEcCtD
Mitoxantrone—Pharyngitis—Capecitabine—colon cancer	5.95e-05	0.00155	CcSEcCtD
Mitoxantrone—Tachycardia—Fluorouracil—colon cancer	5.94e-05	0.00155	CcSEcCtD
Mitoxantrone—Hypotension—Irinotecan—colon cancer	5.94e-05	0.00155	CcSEcCtD
Mitoxantrone—ABCB1—vagina—colon cancer	5.87e-05	0.00473	CbGeAlD
Mitoxantrone—Paraesthesia—Vincristine—colon cancer	5.86e-05	0.00153	CcSEcCtD
Mitoxantrone—Anorexia—Fluorouracil—colon cancer	5.81e-05	0.00152	CcSEcCtD
Mitoxantrone—Paraesthesia—Irinotecan—colon cancer	5.71e-05	0.00149	CcSEcCtD
Mitoxantrone—Hypotension—Fluorouracil—colon cancer	5.69e-05	0.00149	CcSEcCtD
Mitoxantrone—Decreased appetite—Vincristine—colon cancer	5.68e-05	0.00148	CcSEcCtD
Mitoxantrone—Dyspnoea—Irinotecan—colon cancer	5.67e-05	0.00148	CcSEcCtD
Mitoxantrone—Somnolence—Irinotecan—colon cancer	5.65e-05	0.00148	CcSEcCtD
Mitoxantrone—Fatigue—Vincristine—colon cancer	5.63e-05	0.00147	CcSEcCtD
Mitoxantrone—Dyspepsia—Irinotecan—colon cancer	5.6e-05	0.00146	CcSEcCtD
Mitoxantrone—Constipation—Vincristine—colon cancer	5.58e-05	0.00146	CcSEcCtD
Mitoxantrone—Pain—Vincristine—colon cancer	5.58e-05	0.00146	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Fluorouracil—colon cancer	5.55e-05	0.00145	CcSEcCtD
Mitoxantrone—Decreased appetite—Irinotecan—colon cancer	5.53e-05	0.00144	CcSEcCtD
Mitoxantrone—Fatigue—Irinotecan—colon cancer	5.48e-05	0.00143	CcSEcCtD
Mitoxantrone—Paraesthesia—Fluorouracil—colon cancer	5.47e-05	0.00143	CcSEcCtD
Mitoxantrone—Constipation—Irinotecan—colon cancer	5.44e-05	0.00142	CcSEcCtD
Mitoxantrone—Pain—Irinotecan—colon cancer	5.44e-05	0.00142	CcSEcCtD
Mitoxantrone—Dyspnoea—Fluorouracil—colon cancer	5.43e-05	0.00142	CcSEcCtD
Mitoxantrone—Somnolence—Fluorouracil—colon cancer	5.41e-05	0.00141	CcSEcCtD
Mitoxantrone—Chills—Capecitabine—colon cancer	5.38e-05	0.0014	CcSEcCtD
Mitoxantrone—Dyspepsia—Fluorouracil—colon cancer	5.36e-05	0.0014	CcSEcCtD
Mitoxantrone—Arrhythmia—Capecitabine—colon cancer	5.35e-05	0.0014	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Vincristine—colon cancer	5.34e-05	0.00139	CcSEcCtD
Mitoxantrone—Decreased appetite—Fluorouracil—colon cancer	5.29e-05	0.00138	CcSEcCtD
Mitoxantrone—Alopecia—Capecitabine—colon cancer	5.29e-05	0.00138	CcSEcCtD
Mitoxantrone—Pancytopenia—Methotrexate—colon cancer	5.29e-05	0.00138	CcSEcCtD
Mitoxantrone—Feeling abnormal—Irinotecan—colon cancer	5.24e-05	0.00137	CcSEcCtD
Mitoxantrone—Erythema—Capecitabine—colon cancer	5.22e-05	0.00136	CcSEcCtD
Mitoxantrone—Neutropenia—Methotrexate—colon cancer	5.21e-05	0.00136	CcSEcCtD
Mitoxantrone—Pain—Fluorouracil—colon cancer	5.21e-05	0.00136	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Irinotecan—colon cancer	5.2e-05	0.00136	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Methotrexate—colon cancer	5.18e-05	0.00135	CcSEcCtD
Mitoxantrone—Abdominal pain—Vincristine—colon cancer	5.16e-05	0.00135	CcSEcCtD
Mitoxantrone—Body temperature increased—Vincristine—colon cancer	5.16e-05	0.00135	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Methotrexate—colon cancer	5.13e-05	0.00134	CcSEcCtD
Mitoxantrone—Dysgeusia—Capecitabine—colon cancer	5.11e-05	0.00133	CcSEcCtD
Mitoxantrone—Back pain—Capecitabine—colon cancer	5.04e-05	0.00132	CcSEcCtD
Mitoxantrone—Body temperature increased—Irinotecan—colon cancer	5.03e-05	0.00131	CcSEcCtD
Mitoxantrone—Abdominal pain—Irinotecan—colon cancer	5.03e-05	0.00131	CcSEcCtD
Mitoxantrone—Feeling abnormal—Fluorouracil—colon cancer	5.02e-05	0.00131	CcSEcCtD
Mitoxantrone—Pneumonia—Methotrexate—colon cancer	5e-05	0.0013	CcSEcCtD
Mitoxantrone—Drowsiness—Methotrexate—colon cancer	4.97e-05	0.0013	CcSEcCtD
Mitoxantrone—ABCB1—liver—colon cancer	4.95e-05	0.00399	CbGeAlD
Mitoxantrone—Vision blurred—Capecitabine—colon cancer	4.91e-05	0.00128	CcSEcCtD
Mitoxantrone—Renal failure—Methotrexate—colon cancer	4.88e-05	0.00127	CcSEcCtD
Mitoxantrone—Stomatitis—Methotrexate—colon cancer	4.84e-05	0.00126	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Capecitabine—colon cancer	4.84e-05	0.00126	CcSEcCtD
Mitoxantrone—Urticaria—Fluorouracil—colon cancer	4.84e-05	0.00126	CcSEcCtD
Mitoxantrone—Conjunctivitis—Methotrexate—colon cancer	4.83e-05	0.00126	CcSEcCtD
Mitoxantrone—Anaemia—Capecitabine—colon cancer	4.82e-05	0.00126	CcSEcCtD
Mitoxantrone—Body temperature increased—Fluorouracil—colon cancer	4.81e-05	0.00126	CcSEcCtD
Mitoxantrone—Hypersensitivity—Vincristine—colon cancer	4.81e-05	0.00126	CcSEcCtD
Mitoxantrone—Sweating—Methotrexate—colon cancer	4.76e-05	0.00124	CcSEcCtD
Mitoxantrone—Haematuria—Methotrexate—colon cancer	4.74e-05	0.00124	CcSEcCtD
Mitoxantrone—Malaise—Capecitabine—colon cancer	4.7e-05	0.00123	CcSEcCtD
Mitoxantrone—Hypersensitivity—Irinotecan—colon cancer	4.69e-05	0.00122	CcSEcCtD
Mitoxantrone—Asthenia—Vincristine—colon cancer	4.69e-05	0.00122	CcSEcCtD
Mitoxantrone—Leukopenia—Capecitabine—colon cancer	4.67e-05	0.00122	CcSEcCtD
Mitoxantrone—Agranulocytosis—Methotrexate—colon cancer	4.64e-05	0.00121	CcSEcCtD
Mitoxantrone—Asthenia—Irinotecan—colon cancer	4.56e-05	0.00119	CcSEcCtD
Mitoxantrone—Cough—Capecitabine—colon cancer	4.55e-05	0.00119	CcSEcCtD
Mitoxantrone—Hypertension—Capecitabine—colon cancer	4.5e-05	0.00118	CcSEcCtD
Mitoxantrone—Hypersensitivity—Fluorouracil—colon cancer	4.49e-05	0.00117	CcSEcCtD
Mitoxantrone—Haemoglobin—Methotrexate—colon cancer	4.48e-05	0.00117	CcSEcCtD
Mitoxantrone—Diarrhoea—Vincristine—colon cancer	4.47e-05	0.00117	CcSEcCtD
Mitoxantrone—Haemorrhage—Methotrexate—colon cancer	4.46e-05	0.00116	CcSEcCtD
Mitoxantrone—Hepatitis—Methotrexate—colon cancer	4.46e-05	0.00116	CcSEcCtD
Mitoxantrone—Arthralgia—Capecitabine—colon cancer	4.44e-05	0.00116	CcSEcCtD
Mitoxantrone—Chest pain—Capecitabine—colon cancer	4.44e-05	0.00116	CcSEcCtD
Mitoxantrone—Myalgia—Capecitabine—colon cancer	4.44e-05	0.00116	CcSEcCtD
Mitoxantrone—Pharyngitis—Methotrexate—colon cancer	4.43e-05	0.00116	CcSEcCtD
Mitoxantrone—Anxiety—Capecitabine—colon cancer	4.42e-05	0.00116	CcSEcCtD
Mitoxantrone—Discomfort—Capecitabine—colon cancer	4.39e-05	0.00115	CcSEcCtD
Mitoxantrone—Diarrhoea—Irinotecan—colon cancer	4.35e-05	0.00114	CcSEcCtD
Mitoxantrone—Confusional state—Capecitabine—colon cancer	4.29e-05	0.00112	CcSEcCtD
Mitoxantrone—Oedema—Capecitabine—colon cancer	4.26e-05	0.00111	CcSEcCtD
Mitoxantrone—Infection—Capecitabine—colon cancer	4.23e-05	0.0011	CcSEcCtD
Mitoxantrone—Shock—Capecitabine—colon cancer	4.19e-05	0.00109	CcSEcCtD
Mitoxantrone—Diarrhoea—Fluorouracil—colon cancer	4.17e-05	0.00109	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Capecitabine—colon cancer	4.17e-05	0.00109	CcSEcCtD
Mitoxantrone—Tachycardia—Capecitabine—colon cancer	4.15e-05	0.00108	CcSEcCtD
Mitoxantrone—Vomiting—Vincristine—colon cancer	4.15e-05	0.00108	CcSEcCtD
Mitoxantrone—Skin disorder—Capecitabine—colon cancer	4.13e-05	0.00108	CcSEcCtD
Mitoxantrone—Rash—Vincristine—colon cancer	4.12e-05	0.00107	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Capecitabine—colon cancer	4.11e-05	0.00107	CcSEcCtD
Mitoxantrone—Dermatitis—Vincristine—colon cancer	4.11e-05	0.00107	CcSEcCtD
Mitoxantrone—Headache—Vincristine—colon cancer	4.09e-05	0.00107	CcSEcCtD
Mitoxantrone—Anorexia—Capecitabine—colon cancer	4.06e-05	0.00106	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—TYMS—colon cancer	4.05e-05	0.00233	CbGpPWpGaD
Mitoxantrone—Vomiting—Irinotecan—colon cancer	4.04e-05	0.00106	CcSEcCtD
Mitoxantrone—Rash—Irinotecan—colon cancer	4.01e-05	0.00105	CcSEcCtD
Mitoxantrone—Dermatitis—Irinotecan—colon cancer	4.01e-05	0.00105	CcSEcCtD
Mitoxantrone—Chills—Methotrexate—colon cancer	4e-05	0.00104	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	3.99e-05	0.00229	CbGpPWpGaD
Mitoxantrone—Headache—Irinotecan—colon cancer	3.98e-05	0.00104	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	3.98e-05	0.00229	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—SRC—colon cancer	3.98e-05	0.00229	CbGpPWpGaD
Mitoxantrone—Hypotension—Capecitabine—colon cancer	3.98e-05	0.00104	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	3.95e-05	0.00227	CbGpPWpGaD
Mitoxantrone—Alopecia—Methotrexate—colon cancer	3.94e-05	0.00103	CcSEcCtD
Mitoxantrone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	3.92e-05	0.00225	CbGpPWpGaD
Mitoxantrone—Erythema—Methotrexate—colon cancer	3.88e-05	0.00101	CcSEcCtD
Mitoxantrone—Nausea—Vincristine—colon cancer	3.88e-05	0.00101	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Capecitabine—colon cancer	3.88e-05	0.00101	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	3.88e-05	0.00223	CbGpPWpGaD
Mitoxantrone—Vomiting—Fluorouracil—colon cancer	3.87e-05	0.00101	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	3.86e-05	0.00222	CbGpPWpGaD
Mitoxantrone—Rash—Fluorouracil—colon cancer	3.84e-05	0.001	CcSEcCtD
Mitoxantrone—Dermatitis—Fluorouracil—colon cancer	3.84e-05	0.001	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—colon cancer	3.83e-05	0.0022	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Capecitabine—colon cancer	3.82e-05	0.000998	CcSEcCtD
Mitoxantrone—Headache—Fluorouracil—colon cancer	3.82e-05	0.000996	CcSEcCtD
Mitoxantrone—Dysgeusia—Methotrexate—colon cancer	3.8e-05	0.000993	CcSEcCtD
Mitoxantrone—Dyspnoea—Capecitabine—colon cancer	3.79e-05	0.000991	CcSEcCtD
Mitoxantrone—ABCB1—lymph node—colon cancer	3.79e-05	0.00306	CbGeAlD
Mitoxantrone—Nausea—Irinotecan—colon cancer	3.78e-05	0.000986	CcSEcCtD
Mitoxantrone—Back pain—Methotrexate—colon cancer	3.76e-05	0.00098	CcSEcCtD
Mitoxantrone—Dyspepsia—Capecitabine—colon cancer	3.75e-05	0.000978	CcSEcCtD
Mitoxantrone—Decreased appetite—Capecitabine—colon cancer	3.7e-05	0.000966	CcSEcCtD
Mitoxantrone—Fatigue—Capecitabine—colon cancer	3.67e-05	0.000958	CcSEcCtD
Mitoxantrone—Vision blurred—Methotrexate—colon cancer	3.66e-05	0.000955	CcSEcCtD
Mitoxantrone—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	3.64e-05	0.00209	CbGpPWpGaD
Mitoxantrone—Constipation—Capecitabine—colon cancer	3.64e-05	0.00095	CcSEcCtD
Mitoxantrone—Pain—Capecitabine—colon cancer	3.64e-05	0.00095	CcSEcCtD
Mitoxantrone—Nausea—Fluorouracil—colon cancer	3.62e-05	0.000944	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Methotrexate—colon cancer	3.6e-05	0.00094	CcSEcCtD
Mitoxantrone—Anaemia—Methotrexate—colon cancer	3.59e-05	0.000937	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—CDKN1A—colon cancer	3.57e-05	0.00205	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—MYC—colon cancer	3.57e-05	0.00205	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	3.56e-05	0.00204	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—HRAS—colon cancer	3.54e-05	0.00204	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	3.54e-05	0.00203	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Capecitabine—colon cancer	3.51e-05	0.000916	CcSEcCtD
Mitoxantrone—Malaise—Methotrexate—colon cancer	3.5e-05	0.000914	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	3.49e-05	0.002	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—colon cancer	3.49e-05	0.002	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Capecitabine—colon cancer	3.48e-05	0.000909	CcSEcCtD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—colon cancer	3.48e-05	0.002	CbGpPWpGaD
Mitoxantrone—Leukopenia—Methotrexate—colon cancer	3.48e-05	0.000907	CcSEcCtD
Mitoxantrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	3.47e-05	0.00199	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CA7—colon cancer	3.46e-05	0.00199	CbGpPWpGaD
Mitoxantrone—Cough—Methotrexate—colon cancer	3.39e-05	0.000884	CcSEcCtD
Mitoxantrone—Urticaria—Capecitabine—colon cancer	3.38e-05	0.000883	CcSEcCtD
Mitoxantrone—Body temperature increased—Capecitabine—colon cancer	3.36e-05	0.000878	CcSEcCtD
Mitoxantrone—Abdominal pain—Capecitabine—colon cancer	3.36e-05	0.000878	CcSEcCtD
Mitoxantrone—Convulsion—Methotrexate—colon cancer	3.36e-05	0.000878	CcSEcCtD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—CDKN1A—colon cancer	3.36e-05	0.00193	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—CDKN1A—colon cancer	3.36e-05	0.00193	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CA7—colon cancer	3.34e-05	0.00192	CbGpPWpGaD
Mitoxantrone—Arthralgia—Methotrexate—colon cancer	3.31e-05	0.000863	CcSEcCtD
Mitoxantrone—Myalgia—Methotrexate—colon cancer	3.31e-05	0.000863	CcSEcCtD
Mitoxantrone—Chest pain—Methotrexate—colon cancer	3.31e-05	0.000863	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—colon cancer	3.3e-05	0.00189	CbGpPWpGaD
Mitoxantrone—Discomfort—Methotrexate—colon cancer	3.27e-05	0.000853	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—MYC—colon cancer	3.2e-05	0.00184	CbGpPWpGaD
Mitoxantrone—Confusional state—Methotrexate—colon cancer	3.19e-05	0.000834	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—NRAS—colon cancer	3.18e-05	0.00183	CbGpPWpGaD
Mitoxantrone—Anaphylactic shock—Methotrexate—colon cancer	3.17e-05	0.000827	CcSEcCtD
Mitoxantrone—Infection—Methotrexate—colon cancer	3.15e-05	0.000822	CcSEcCtD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—ABCB1—colon cancer	3.14e-05	0.0018	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Capecitabine—colon cancer	3.14e-05	0.000819	CcSEcCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—AKT1—colon cancer	3.13e-05	0.0018	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—CDKN1A—colon cancer	3.11e-05	0.00179	CbGpPWpGaD
Mitoxantrone—Thrombocytopenia—Methotrexate—colon cancer	3.1e-05	0.00081	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.1e-05	0.00178	CbGpPWpGaD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	3.08e-05	0.00177	CbGpPWpGaD
Mitoxantrone—Skin disorder—Methotrexate—colon cancer	3.08e-05	0.000803	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Methotrexate—colon cancer	3.06e-05	0.0008	CcSEcCtD
Mitoxantrone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—colon cancer	3.06e-05	0.00176	CbGpPWpGaD
Mitoxantrone—Asthenia—Capecitabine—colon cancer	3.05e-05	0.000797	CcSEcCtD
Mitoxantrone—ABCG2—Metabolism—CA7—colon cancer	3.04e-05	0.00175	CbGpPWpGaD
Mitoxantrone—Anorexia—Methotrexate—colon cancer	3.02e-05	0.000788	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—NRAS—colon cancer	2.99e-05	0.00172	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—NRAS—colon cancer	2.99e-05	0.00172	CbGpPWpGaD
Mitoxantrone—Hypotension—Methotrexate—colon cancer	2.96e-05	0.000773	CcSEcCtD
Mitoxantrone—Diarrhoea—Capecitabine—colon cancer	2.91e-05	0.00076	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—EGFR—colon cancer	2.9e-05	0.00167	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Methotrexate—colon cancer	2.89e-05	0.000754	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—PPARG—colon cancer	2.87e-05	0.00165	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—PIK3CA—colon cancer	2.87e-05	0.00165	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Methotrexate—colon cancer	2.85e-05	0.000743	CcSEcCtD
Mitoxantrone—Dyspnoea—Methotrexate—colon cancer	2.82e-05	0.000737	CcSEcCtD
Mitoxantrone—Somnolence—Methotrexate—colon cancer	2.82e-05	0.000735	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CCND1—colon cancer	2.81e-05	0.00161	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MLH1—colon cancer	2.8e-05	0.00161	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—colon cancer	2.8e-05	0.00161	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—EP300—colon cancer	2.79e-05	0.0016	CbGpPWpGaD
Mitoxantrone—Dyspepsia—Methotrexate—colon cancer	2.79e-05	0.000728	CcSEcCtD
Mitoxantrone—BTK—Immune System—BCL10—colon cancer	2.79e-05	0.0016	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—NRAS—colon cancer	2.77e-05	0.00159	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Methotrexate—colon cancer	2.75e-05	0.000719	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—KRAS—colon cancer	2.74e-05	0.00157	CbGpPWpGaD
Mitoxantrone—Fatigue—Methotrexate—colon cancer	2.73e-05	0.000713	CcSEcCtD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—EGFR—colon cancer	2.73e-05	0.00157	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—EGFR—colon cancer	2.73e-05	0.00157	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDKN1A—colon cancer	2.72e-05	0.00156	CbGpPWpGaD
Mitoxantrone—Pain—Methotrexate—colon cancer	2.71e-05	0.000707	CcSEcCtD
Mitoxantrone—Vomiting—Capecitabine—colon cancer	2.71e-05	0.000706	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	2.7e-05	0.00155	CbGpPWpGaD
Mitoxantrone—Rash—Capecitabine—colon cancer	2.68e-05	0.000701	CcSEcCtD
Mitoxantrone—Dermatitis—Capecitabine—colon cancer	2.68e-05	0.0007	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—BUB1B—colon cancer	2.67e-05	0.00153	CbGpPWpGaD
Mitoxantrone—Headache—Capecitabine—colon cancer	2.67e-05	0.000696	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—VEGFA—colon cancer	2.64e-05	0.00152	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—colon cancer	2.63e-05	0.00151	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Methotrexate—colon cancer	2.61e-05	0.000682	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Methotrexate—colon cancer	2.59e-05	0.000676	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—KRAS—colon cancer	2.58e-05	0.00148	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—KRAS—colon cancer	2.58e-05	0.00148	CbGpPWpGaD
Mitoxantrone—Nausea—Capecitabine—colon cancer	2.53e-05	0.00066	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—EGFR—colon cancer	2.52e-05	0.00145	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CD8A—colon cancer	2.52e-05	0.00145	CbGpPWpGaD
Mitoxantrone—Urticaria—Methotrexate—colon cancer	2.52e-05	0.000657	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—PIK3CA—colon cancer	2.52e-05	0.00145	CbGpPWpGaD
Mitoxantrone—Body temperature increased—Methotrexate—colon cancer	2.5e-05	0.000654	CcSEcCtD
Mitoxantrone—Abdominal pain—Methotrexate—colon cancer	2.5e-05	0.000654	CcSEcCtD
Mitoxantrone—ABCC1—Disease—LGR5—colon cancer	2.5e-05	0.00144	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CHST5—colon cancer	2.5e-05	0.00144	CbGpPWpGaD
Mitoxantrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	2.41e-05	0.00139	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—BUB1B—colon cancer	2.38e-05	0.00137	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—KRAS—colon cancer	2.38e-05	0.00137	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—PIK3CA—colon cancer	2.37e-05	0.00136	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PIK3CA—colon cancer	2.37e-05	0.00136	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.35e-05	0.00135	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—AKT1—colon cancer	2.35e-05	0.00135	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Methotrexate—colon cancer	2.33e-05	0.000609	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—HRAS—colon cancer	2.33e-05	0.00134	CbGpPWpGaD
Mitoxantrone—Asthenia—Methotrexate—colon cancer	2.27e-05	0.000593	CcSEcCtD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	2.27e-05	0.0013	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—MYC—colon cancer	2.25e-05	0.00129	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—BCL2L1—colon cancer	2.24e-05	0.00129	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—PIK3CA—colon cancer	2.19e-05	0.00126	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—HRAS—colon cancer	2.19e-05	0.00126	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—HRAS—colon cancer	2.19e-05	0.00126	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.18e-05	0.00126	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CA7—colon cancer	2.18e-05	0.00125	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Methotrexate—colon cancer	2.17e-05	0.000566	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—FGFR3—colon cancer	2.14e-05	0.00123	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.13e-05	0.00122	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.11e-05	0.00121	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ODC1—colon cancer	2.09e-05	0.0012	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CHST5—colon cancer	2.09e-05	0.0012	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—FGFR3—colon cancer	2.06e-05	0.00118	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.06e-05	0.00118	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—AKT1—colon cancer	2.06e-05	0.00118	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—TYMS—colon cancer	2.04e-05	0.00117	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—HRAS—colon cancer	2.03e-05	0.00116	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CHST5—colon cancer	2.03e-05	0.00116	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ODC1—colon cancer	2.03e-05	0.00116	CbGpPWpGaD
Mitoxantrone—Vomiting—Methotrexate—colon cancer	2.01e-05	0.000526	CcSEcCtD
Mitoxantrone—Rash—Methotrexate—colon cancer	2e-05	0.000522	CcSEcCtD
Mitoxantrone—Dermatitis—Methotrexate—colon cancer	2e-05	0.000521	CcSEcCtD
Mitoxantrone—Headache—Methotrexate—colon cancer	1.98e-05	0.000518	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.96e-05	0.00112	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—AKT1—colon cancer	1.93e-05	0.00111	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	1.93e-05	0.00111	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.9e-05	0.00109	CbGpPWpGaD
Mitoxantrone—Nausea—Methotrexate—colon cancer	1.88e-05	0.000491	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—EP300—colon cancer	1.88e-05	0.00108	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.85e-05	0.00107	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ODC1—colon cancer	1.84e-05	0.00106	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CHST5—colon cancer	1.84e-05	0.00106	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TYMS—colon cancer	1.83e-05	0.00105	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	1.81e-05	0.00104	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—AXIN2—colon cancer	1.8e-05	0.00103	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—AKT1—colon cancer	1.79e-05	0.00103	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CDH1—colon cancer	1.74e-05	0.001	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.71e-05	0.00098	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.7e-05	0.000978	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—AKT1—colon cancer	1.69e-05	0.000968	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.67e-05	0.000959	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	1.67e-05	0.000958	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CA7—colon cancer	1.64e-05	0.000945	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.58e-05	0.000905	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CD8A—colon cancer	1.53e-05	0.000877	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	1.51e-05	0.000866	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—CASP3—colon cancer	1.46e-05	0.000838	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.45e-05	0.000832	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	1.43e-05	0.000821	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.4e-05	0.000805	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	1.39e-05	0.000799	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—colon cancer	1.34e-05	0.000773	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	1.34e-05	0.00077	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CTNNB1—colon cancer	1.34e-05	0.000768	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CHST5—colon cancer	1.32e-05	0.00076	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ODC1—colon cancer	1.32e-05	0.00076	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CDKN1A—colon cancer	1.31e-05	0.000751	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—BCL2L1—colon cancer	1.31e-05	0.000751	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CDKN1A—colon cancer	1.25e-05	0.000721	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—FGFR3—colon cancer	1.25e-05	0.000718	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EP300—colon cancer	1.24e-05	0.000714	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—VEGFA—colon cancer	1.24e-05	0.000711	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—SRC—colon cancer	1.21e-05	0.000695	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.18e-05	0.00068	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—ABCB1—colon cancer	1.18e-05	0.000679	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—NRAS—colon cancer	1.16e-05	0.000668	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—SRC—colon cancer	1.16e-05	0.000667	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—TGFB1—colon cancer	1.14e-05	0.000652	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—NRAS—colon cancer	1.12e-05	0.000642	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EGFR—colon cancer	1.06e-05	0.000609	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CDH1—colon cancer	1.06e-05	0.000606	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—ABCB1—colon cancer	1.04e-05	0.000597	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCND1—colon cancer	1.03e-05	0.000591	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	1.02e-05	0.000586	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—EGFR—colon cancer	1.02e-05	0.000585	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CA7—colon cancer	1.01e-05	0.000582	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—KRAS—colon cancer	1e-05	0.000575	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CHST5—colon cancer	9.97e-06	0.000573	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—ODC1—colon cancer	9.97e-06	0.000573	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN1A—colon cancer	9.96e-06	0.000572	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—KRAS—colon cancer	9.61e-06	0.000552	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—EP300—colon cancer	9.48e-06	0.000544	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCND1—colon cancer	9.21e-06	0.000529	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—PIK3CA—colon cancer	9.2e-06	0.000528	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	9.11e-06	0.000524	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDKN1A—colon cancer	8.91e-06	0.000512	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—PIK3CA—colon cancer	8.83e-06	0.000507	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.65e-06	0.000497	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HRAS—colon cancer	8.51e-06	0.000489	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—EP300—colon cancer	8.47e-06	0.000487	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.36e-06	0.00048	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—MYC—colon cancer	8.26e-06	0.000474	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HRAS—colon cancer	8.17e-06	0.000469	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CTNNB1—colon cancer	7.79e-06	0.000448	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	7.75e-06	0.000445	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CDKN1A—colon cancer	7.61e-06	0.000437	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—AKT1—colon cancer	7.51e-06	0.000432	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MYC—colon cancer	7.38e-06	0.000424	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EP300—colon cancer	7.24e-06	0.000416	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—AKT1—colon cancer	7.21e-06	0.000414	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	7.19e-06	0.000413	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—SRC—colon cancer	7.04e-06	0.000405	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	7e-06	0.000402	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	6.93e-06	0.000398	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.8e-06	0.000391	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	6.77e-06	0.000389	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—NRAS—colon cancer	6.77e-06	0.000389	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.58e-06	0.000378	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	6.45e-06	0.00037	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	6.27e-06	0.00036	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EGFR—colon cancer	6.17e-06	0.000355	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ODC1—colon cancer	6.14e-06	0.000353	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CHST5—colon cancer	6.14e-06	0.000353	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	6.1e-06	0.000351	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—colon cancer	6.06e-06	0.000348	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—KRAS—colon cancer	5.83e-06	0.000335	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.66e-06	0.000325	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	5.62e-06	0.000323	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	5.6e-06	0.000322	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ABCB1—colon cancer	5.54e-06	0.000318	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	5.49e-06	0.000316	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.47e-06	0.000314	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—TYMS—colon cancer	5.44e-06	0.000312	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—PIK3CA—colon cancer	5.36e-06	0.000308	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ABCB1—colon cancer	5.35e-06	0.000308	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—TYMS—colon cancer	5.26e-06	0.000302	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	5.19e-06	0.000298	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—FGFR3—colon cancer	5.19e-06	0.000298	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HRAS—colon cancer	4.96e-06	0.000285	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ABCB1—colon cancer	4.87e-06	0.00028	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—TYMS—colon cancer	4.78e-06	0.000275	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.77e-06	0.000274	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—APC—colon cancer	4.76e-06	0.000274	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	4.61e-06	0.000265	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—BRAF—colon cancer	4.48e-06	0.000257	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—AKT1—colon cancer	4.38e-06	0.000251	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.19e-06	0.00024	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.05e-06	0.000233	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.9e-06	0.000224	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PPARG—colon cancer	3.85e-06	0.000221	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PPARG—colon cancer	3.72e-06	0.000214	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTGS2—colon cancer	3.62e-06	0.000208	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ABCB1—colon cancer	3.5e-06	0.000201	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—TYMS—colon cancer	3.43e-06	0.000197	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PPARG—colon cancer	3.39e-06	0.000195	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CTNNB1—colon cancer	3.24e-06	0.000186	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CDKN1A—colon cancer	3.16e-06	0.000182	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTGS2—colon cancer	3.03e-06	0.000174	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EP300—colon cancer	3.01e-06	0.000173	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTGS2—colon cancer	2.93e-06	0.000168	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—SRC—colon cancer	2.93e-06	0.000168	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NRAS—colon cancer	2.81e-06	0.000162	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTGS2—colon cancer	2.67e-06	0.000153	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MYC—colon cancer	2.62e-06	0.000151	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TGFB1—colon cancer	2.62e-06	0.00015	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—TYMS—colon cancer	2.59e-06	0.000149	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EGFR—colon cancer	2.56e-06	0.000147	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—EP300—colon cancer	2.52e-06	0.000145	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—EP300—colon cancer	2.44e-06	0.00014	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PPARG—colon cancer	2.43e-06	0.00014	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—KRAS—colon cancer	2.42e-06	0.000139	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PIK3CA—colon cancer	2.23e-06	0.000128	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—EP300—colon cancer	2.22e-06	0.000127	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HRAS—colon cancer	2.06e-06	0.000118	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTGS2—colon cancer	1.91e-06	0.00011	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PIK3CA—colon cancer	1.86e-06	0.000107	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PPARG—colon cancer	1.83e-06	0.000105	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—AKT1—colon cancer	1.82e-06	0.000104	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PIK3CA—colon cancer	1.8e-06	0.000104	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PIK3CA—colon cancer	1.64e-06	9.42e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ABCB1—colon cancer	1.62e-06	9.32e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—TYMS—colon cancer	1.59e-06	9.15e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—EP300—colon cancer	1.59e-06	9.14e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—AKT1—colon cancer	1.52e-06	8.75e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—AKT1—colon cancer	1.47e-06	8.46e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTGS2—colon cancer	1.44e-06	8.28e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—AKT1—colon cancer	1.34e-06	7.7e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—EP300—colon cancer	1.2e-06	6.89e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PIK3CA—colon cancer	1.18e-06	6.76e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PPARG—colon cancer	1.13e-06	6.48e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—AKT1—colon cancer	9.62e-07	5.53e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTGS2—colon cancer	8.88e-07	5.1e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PIK3CA—colon cancer	8.87e-07	5.09e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—EP300—colon cancer	7.39e-07	4.24e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—AKT1—colon cancer	7.24e-07	4.16e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PIK3CA—colon cancer	5.46e-07	3.14e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—AKT1—colon cancer	4.46e-07	2.56e-05	CbGpPWpGaD
